ReviewCurrent medicinal chemistry2015
Erythropoietin in stroke therapy: friend or foe.
Review in Current medicinal chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- The Neuroprotective Effect of Erythropoietin on the Optic Nerve and Spinal Cord in Rats with Experimental Autoimmune Encephalomyelitis through the Activation of the Extracellular Signal-Regulated Kinase 1/2 Signaling Pathway.International journal of molecular sciences · 2024Article
- Role of Microglial Modulation in Therapies for Perinatal Brain Injuries Leading to Neurodevelopmental Disorders.Advances in neurobiology · 2024Review
- Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Adding erythropoietin to intravenous methylprednisolone in acute treatment of attacks of neuromyelitis optica spectrum disorders: A randomized controlled trial.Current journal of neurology · 2022Article
- A Novel Plant-Produced Asialo-rhuEPO Protects Brain from Ischemic Damage Without Erythropoietic Action.Translational stroke research · 2022Article
- Combination of stem cell therapy and acupuncture to treat ischemic stroke: a prospective review.Stem cell research & therapy · 2022Review
- Erythropoietin administration exerted neuroprotective effects against cardiac ischemia/reperfusion injury.Current research in pharmacology and drug discovery · 2022Article
- Pulsed Electromagnetic Fields Stimulate HIF-1α-Independent VEGF Release in 1321N1 Human Astrocytes Protecting Neuron-Like SH-SY5Y Cells from Oxygen-Glucose Deprivation.International journal of molecular sciences · 2020Article
- Development of a Neuroprotective Erythropoietin Modified with a Novel Carrier for the Blood-Brain Barrier.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Article
- Viability and Contractility of Rat Brain Pericytes in Conditions That Mimic Stroke; anFrontiers in neuroscience · 2019Article
- The Orphan Cytokine Receptor CRLF3 Emerged With the Origin of the Nervous System and Is a Neuroprotective Erythropoietin Receptor in Locusts.Frontiers in molecular neuroscience · 2019Article
- Circulating biomarkers in extremely preterm infants associated with ultrasound indicators of brain damage.European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · 2018Observational
- Erythropoietin reduces experimental autoimmune encephalomyelitis severity via neuroprotective mechanisms.Journal of neuroinflammation · 2017Article
- The role of erythropoietin in remote renal preconditioning on hippocampus ischemia/reperfusion injury.The journal of physiological sciences : JPS · 2017Article
- Sub-acute systemic erythropoietin administration reduces ischemic brain injury in an age-dependent manner.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Recombinant human erythropoietin (rhEPO), over the past decade, was hailed as an auspicious therapeutic strategy for various types of brain injuries. The promising results from experiments conducted in animal models of stroke led to a hurried clinical trial that was swiftly aborted in Phase II. The multiple neuroprotective modalities of rhEPO failed to translate smoothly to human adult ischemic brain injury and provided limited aid to neonates. In light of the antithetical results, several questions were raised as to why and how this clinical trial failed. There was bolstering evidence from the preliminary studies that pointed to a bright future. Therefore, the objective of this review is to address these questions by discussing the signaling pathways of rhEPO that are reported to mediate the neuroprotective effect in various animal models of brain injury. Major biomedical bibliographical databases (MEDLINE, ISI, PubMed, and Cochrane Library) were searched with the use of keywords such as erythropoietin, stroke, neonatal hypoxia ischemia, intracerebral hemorrhage, etc. This article will discuss the confounding factors that influence the efficacy of rhEPO treatment hence challenging its clinical translatability. Lastly, rhEPO may still be a promising therapeutic candidate for neonates in spite of its shortcoming in clinical trial if caution is taken with the dose and duration of its administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.